These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 20887341)

  • 1. Roflumilast: clinical benefit in patients suffering from COPD.
    Ulrik CS; Calverley PM
    Clin Respir J; 2010 Oct; 4(4):197-201. PubMed ID: 20887341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roflumilast for the treatment of chronic obstructive pulmonary disease.
    Rabe KF
    Expert Rev Respir Med; 2010 Oct; 4(5):543-55. PubMed ID: 20649375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
    Pinner NA; Hamilton LA; Hughes A
    Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roflumilast for severe COPD?
    Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.
    Gross NJ; Giembycz MA; Rennard SI
    COPD; 2010 Apr; 7(2):141-53. PubMed ID: 20397815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phosphodiesterase-4 inhibitors: roflumilast].
    Izquierdo Alonso JL
    Rev Clin Esp; 2011 Mar; 211 Suppl 2():22-30. PubMed ID: 21596170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roflumilast: a novel treatment for chronic obstructive pulmonary disease.
    Reid DJ; Pham NT
    Ann Pharmacother; 2012 Apr; 46(4):521-9. PubMed ID: 22433610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical profile of roflumilast].
    Izquierdo Alonso JL
    Arch Bronconeumol; 2010 Dec; 46 Suppl 10():25-32. PubMed ID: 21316553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduce disease burden and improve lung function-roflumilast: approved for moderate to severe COPD: update for the clinical nurse specialist.
    O'Malley P
    Clin Nurse Spec; 2011; 25(4):176-7. PubMed ID: 21654371
    [No Abstract]   [Full Text] [Related]  

  • 11. Roflumilast (Daliresp) for COPD.
    Med Lett Drugs Ther; 2011 Jul; 53(1369):59-60. PubMed ID: 21778965
    [No Abstract]   [Full Text] [Related]  

  • 12. [Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease].
    Kreutzkamp B
    Med Monatsschr Pharm; 2010 Jul; 33(7):236-43. PubMed ID: 20687460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New goals in COPD treatment. From symptom control to prevention of exacerbations].
    Vetter C
    MMW Fortschr Med; 2011 Dec; 153(48):48-9. PubMed ID: 22299261
    [No Abstract]   [Full Text] [Related]  

  • 14. Roflumilast: doubtful efficacy but clear harms in COPD.
    Prescrire Int; 2013 Jan; 22(134):5-9. PubMed ID: 23367674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].
    Martínez FJ
    Arch Bronconeumol; 2010 Nov; 46 Suppl 9():8-11. PubMed ID: 21320811
    [No Abstract]   [Full Text] [Related]  

  • 16. Roflumilast for asthma and chronic obstructive pulmonary disease.
    Cowan C
    Issues Emerg Health Technol; 2005 Oct; (74):1-4. PubMed ID: 16317827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.
    Yan JH; Gu WJ; Pan L
    Pulm Pharmacol Ther; 2014 Feb; 27(1):83-9. PubMed ID: 23624309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
    Moll K; Sun SX; Ellis JJ; Howe A; Amin A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():565-76. PubMed ID: 25834417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
    Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
    Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD. A cost-effectiveness analysis for Germany].
    Nowak D; Ehlken B; Kotchie R; Wecht S; Magnussen H
    Dtsch Med Wochenschr; 2013 Jan; 138(4):119-25. PubMed ID: 23322425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.